搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
News Medical
2 天
New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering ...
NNC2215, a glucose-sensitive insulin, offers improved glycemic control by dynamically adjusting to blood sugar levels, ...
New Atlas
3 天
‘Insulin with a switch’ will help diabetics avoid dangerous hypos
An insulin that switches itself on and off in response to blood glucose levels has proven successful in lowering the risk of ...
5 天
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to ...
ophthalmologyadvisor
5 天
Once-Weekly Insulin Inferior to Tirzepatide for Glycemic Control, Weight Loss
Once-weekly insulin vs once-weekly tirzepatide demonstrated superior safety profiles but inferior weight loss and glycemic control outcomes.
The Pharma Letter
10 天
FDA slaps another CRL on Zealand Pharma’s dasiglucagon NDA
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application ...
Pharmaceutical Technology
11 天
FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants
The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism ...
BioSpace
11 天
Zealand Hit With CRL for Ultrarare Genetic Disease Treatment
The rejection is related to the timing of the FDA’s reinspection of Zealand’s third-party manufacturer, which previously had ...
12 天
Zealand Pharma: FDA Issues CRL For Dasiglucagon In Congenital Hyperinsulinism
Zealand Pharma A/S (ZEAL) said that the U.S. Food and Drug Administration has issued a Complete Response Letter or CRL for Part 1 of ...
12 天
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
No. 48 / 2024Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinismU.S. Food and ...
12 天
Zealand Pharma Gets FDA Complete Response Letter for Hypoglycemia New Drug Application
Zealand Pharma said it has received a complete response letter from the Food and Drug Administration related to its new drug application for dasiglucagon for the prevention and treatment of ...
12 天
Postbariatric Hypoglycemia Treatment Market Size in the 7MM was ~200 USD Million in 2023 ...
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Postbariatric Hypoglycemia ...
New Atlas
13 天
Glucose-responsive nanotech prevents dangerously low blood sugar
Nanosized particles that release glucagon, the hormone responsible for raising blood glucose levels, on-demand could mean ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈